Keytruda (pembrolizumab) is a medication used to treat various types of cancer, including melanoma, non-small cell lung cancer, head and neck cancer, and others. It is an immunotherapy drug that works by blocking a protein called PD-1, which helps cancer cells evade the immune system.

According to clinical trial results, Keytruda has been shown to be effective in treating melanoma. In a clinical trial of patients with advanced melanoma, 33% of patients had a complete or partial response to Keytruda treatment [3]. In another clinical trial, 40% of patients with advanced melanoma had a complete or partial response to Keytruda [2].

Keytruda has also been shown to be effective in treating non-small cell lung cancer. In a clinical trial of patients with advanced non-small cell lung cancer, those who received Keytruda had a longer progression-free survival time than those who received chemotherapy [2].

However, like all medications, Keytruda may cause side effects. Some common side effects of Keytruda include fatigue, nausea, and rash. More serious side effects may include immune-mediated reactions, such as pneumonitis or colitis [1].

Overall, Keytruda has been shown to be effective in treating certain types of cancer, including melanoma and non-small cell lung cancer. However, as with any medication, it is important to discuss the potential benefits and risks with a healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.medicalnewstoday.com/articles/keytruda
[3] https://www.keytruda.com/melanoma/monotherapy-clinical-trial-results/